Stem Cell Therapy for Hip Osteoarthritis: An Honest 2026 Look

Hip osteoarthritis sits in a tougher spot than knee osteoarthritis. The hip is a deep ball-and-socket joint, harder to reach with an injection, harder to image, and quicker to reach the "bone-on-bone" endpoint that sends people to a surgeon. Total hip replacement is also one of the most successful operations in all of medicine, which raises the bar for any alternative. So the honest question isn't "do stem cells beat hip replacement?" It's "is there a window, before you need the surgery, where regenerative therapy is a reasonable thing to try?"

For many patients there is. This post lays out who fits that window and who doesn't — what the imaging needs to show, which radiographic grades tend to respond, what the published evidence actually says (it's earlier-stage than the knee literature, and we'll be straight about that), the realistic timeline, the cost in Medellín, and the cases where we tell people honestly that a hip replacement is the better path.

Quick answer

For a typical hip osteoarthritis patient in 2026:

• Mild to moderate OA (KL grade I-II): The most reasonable candidates. The joint still has cartilage and a functional shape to work with. Early studies and our clinical experience point to meaningful pain and function gains for many — though not all — patients in this band.
• Moderate to advanced (KL grade III): Stem cells may still reduce pain and buy time, especially combined with hyperbaric oxygen and rehab, but outcomes are more variable and we set expectations accordingly.
• End-stage (KL grade IV, bone-on-bone): Usually not the right call. The cartilage and joint shape are gone; this is where total hip replacement genuinely shines, and we refer.
• Evidence maturity: The hip literature is smaller and earlier-stage than the knee literature. We treat it as promising, not proven, and we say so.
• Cost in Medellín: roughly $4,200 to $5,200 per hip for the injection protocol, plus optional adjuncts.

Why the hip is harder than the knee

If you've read about stem cell therapy for knee osteoarthritis, it's worth understanding why the hip is a different conversation rather than the same procedure on a different joint.

• It's deep. The hip joint sits under thick muscle. Accurate intra-articular delivery requires image guidance (ultrasound or fluoroscopy), not a freehand injection. Precision matters — cells placed outside the capsule don't do the job.
• It loads differently. The hip carries the full mechanical load of the upper body through a small contact area. Once the joint shape deforms, mechanics work against any biological repair.
• It hides its symptoms. Hip OA pain often shows up in the groin, buttock, or even the knee, and people compensate for years. Many patients arrive more advanced than they realize, which is why imaging matters so much.

None of this makes regenerative therapy pointless for the hip. It makes patient selection and delivery technique more important than they are for the knee.

How the hip is graded radiographically

Every treatment conversation starts with your imaging grade. Hip OA is commonly described with the Kellgren-Lawrence (KL) scale — the same radiographic grading framework used across joints — based on joint-space narrowing, osteophytes (bone spurs), sclerosis, and bone deformity. Your orthopedist may also use the Tönnis classification, which maps closely.

If you don't know your grade, ask your orthopedist or request a copy of your radiology report. We also strongly prefer an MRI: X-rays show bone, but MRI shows cartilage, the labrum, and soft tissue — which tells us what we're actually working with.

How mesenchymal stem cells are thought to work in the hip

The mesenchymal stem cells (MSCs) we work with are sourced from screened, donated umbilical cord tissue and expanded in our INVIMA-regulated laboratory. For the hip they're delivered by image-guided intra-articular injection under local anesthetic.

Based on the laboratory and clinical literature, MSCs are understood to act through several mechanisms rather than simply "growing new cartilage":

• Anti-inflammatory and paracrine signaling: MSCs release growth factors and signaling vesicles that can dampen joint inflammation and modulate pain pathways. This is the fastest-appearing effect and likely accounts for much of the early symptom change patients report.
• Immunomodulation: MSCs interact with the joint lining (synovium) and may reduce the chronic low-grade inflammation that characterizes osteoarthritis.
• Support for local repair: A subset of cells may contribute to matrix maintenance. Importantly, the current evidence suggests injections can help symptoms and may support cartilage health, but are generally insufficient to fully regenerate a badly damaged joint surface. We don't claim otherwise.

What the published evidence actually shows

Here's the honest read of the hip-specific literature, which is smaller and earlier-stage than the knee data:

• Mardones et al. (2017, J Hip Preserv Surg): A cohort of patients with hip OA received intra-articular bone-marrow-derived MSC infusions. The authors reported improvements in pain and function and a favorable safety profile — but this is a small, early-phase study, not a large randomized trial.
• Dall'Oca et al. (2019, Acta Biomed): A small retrospective series of patients with conservative-treatment-resistant hip pain treated with adipose-derived MSCs reported significant improvement in Harris Hip Score and WOMAC at six months, with no adverse effects recorded — again, preliminary and short-follow-up.
• Broader OA evidence (e.g. Vega et al., 2015, Transplantation): Randomized data in knee OA showed MSC injection outperformed hyaluronic acid on cartilage measures, which supports the biological rationale — but knee results don't transfer one-to-one to the hip.

The pattern: encouraging early-phase signals for pain and function, a reassuring safety record, and a clear acknowledgment that high-quality randomized hip trials are still limited. We treat this as a reasonable option to consider in the right patient — not a guaranteed outcome, and not a substitute for surgery when surgery is indicated.

Timeline: what to expect

Responses vary, and some patients don't respond at all. For those who do, the general curve looks like this:

Days 1 to 7: Mild post-injection soreness around the joint. Ice, gentle movement, no impact activity. Most patients are walking comfortably within a day or two.

Weeks 2 to 6: The anti-inflammatory effect tends to appear. Patients often notice reduced groin pain, easier sitting-to-standing, and less stiffness after rest.

Months 2 to 4: The window where functional gains are most commonly reported — longer walking distance, easier stairs, improved sleep. This is also when we can tell whether you're a responder.

Months 4 to 12: For responders, benefits often hold or continue gradually, especially when paired with weight management and a structured strengthening program for the hip and core.

Non-responders are usually identifiable by month 4. If you're not improving, we'll say so honestly and discuss whether a second injection is reasonable or whether your case points toward surgery.

Cost: Medellín vs. US

The economics, transparently:

For US patients, trip costs add roughly $1,200 to $2,000 (flights, 5 to 7 nights near the clinic, transfers). Most US carriers don't cover stem cell injections regardless of location, but HSA/FSA funds typically can be used. We provide an itemized English invoice for anyone pursuing out-of-network reimbursement. For the full economics, see our guide on why stem cell therapy costs 60–75% less in Medellín.

Who is — and isn't — a candidate

Candidacy matters more for the hip than almost any other joint. You're more likely to be a reasonable candidate if:

• Your imaging shows KL grade I-III with cartilage and joint shape still present.
• Your pain is real but you're not yet at the point of needing surgery, or you want to delay it.
• You have reasonable joint alignment and no major structural deformity.
• You're willing to commit to rehab and weight management, which meaningfully affect results.

This may not be right for you if any of the following apply:

• KL grade IV / bone-on-bone with severe joint deformity — total hip replacement is the better, more reliable option.
• Avascular necrosis with structural collapse of the femoral head (early AVN is a separate, sometimes treatable conversation; collapsed AVN usually is not).
• Active joint infection or recent septic arthritis.
• Uncontrolled inflammatory arthritis (rheumatoid, psoriatic) — this needs systemic control first.
• Significant mechanical symptoms or a large structural labral problem that needs surgical attention first.

If you fall into the "not right for you" group, we'll tell you directly. We'd rather lose a booking than treat a hip that should be referred to a surgeon.

What a trip to Medellín looks like

For a single-hip case, plan on 5 to 7 nights total:

• Day 0: Arrive at Medellín José María Córdova airport. Bilingual driver pickup, transfer to your hotel in El Poblado.
• Day 1: Consultation with our regenerative medicine physician — imaging review, clinical exam, plan confirmation, pre-procedure labs if needed.
• Day 2: Injection day. Image-guided intra-articular MSC injection under local anesthetic. Afternoon to rest.
• Days 3 to 5: Optional hyperbaric oxygen sessions and a physiotherapy consult to set up your home hip-and-core program. Light walking encouraged; impact activity avoided.
• Day 6 to 7: Final follow-up and discharge instructions. Follow-up at months 3, 6, and 12 happens by video, with optional imaging forwarded from your local provider.

If you're still researching the destination and logistics generally, our complete US patient's guide to stem cell therapy in Medellín walks through the whole process, and our overview of how stem cells are used in orthopedic recovery covers the broader joint picture.

Imaging you'll need before booking

• Weight-bearing AP pelvis and lateral hip X-rays within the last 12 months (gives us your radiographic grade).
• MRI of the affected hip if available (cartilage, labrum, and to rule out avascular necrosis). Within 24 months is ideal.
• Recent orthopedist or rheumatologist notes if you have them.
• A brief written history of symptom onset, what you've tried (injections, PT, NSAIDs), and your goals.

Our regenerative medicine physician reviews each case personally and replies within 48 hours with an honest assessment: whether you're a reasonable candidate, what protocol we'd recommend, realistic expectations for your imaging profile, and a quote. Cases that aren't a good fit are told so.

The bottom line

Total hip replacement is an excellent operation, and for end-stage arthritis nothing biologic competes with it. But there is a real population — patients with KL grade I-III hips, still some cartilage, pain that's affecting life but hasn't reached the surgical endpoint — for whom stem cell therapy is a reasonable, lower-risk thing to try before committing to surgery. The evidence is earlier-stage than the knee data, the delivery needs to be image-guided, and patient selection is everything. If the imaging, the timeline, and your goals line up, it's worth an honest conversation.